-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WgAc+oTrniYUio+gTnPShAEF8vad8T3vYvLIqMtsTrYIjEq5cDQQGFmagcWNhdS/
 M3bPM+Avk4GG4T6LHOm5Pw==

<SEC-DOCUMENT>0001130319-07-000145.txt : 20070306
<SEC-HEADER>0001130319-07-000145.hdr.sgml : 20070306
<ACCEPTANCE-DATETIME>20070306104145
ACCESSION NUMBER:		0001130319-07-000145
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070306
FILED AS OF DATE:		20070306
DATE AS OF CHANGE:		20070306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		07673652

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o35129e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>Form&nbsp;6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Report of Foreign Private Issuer</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>For
the month of March&nbsp;2007<BR>
Commission File Number 000-31062</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Oncolytics Biotech Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into English)</I></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B></DIV>

<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F or </B><B>Form 40-F</B><B>.</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Form&nbsp;20-F <FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form&nbsp;40-F <FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark if the registrant is submitting the </B><B>Form 6-K</B><B> in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;</B><B>101(b)(1)</B><B>: </B><FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark if the registrant is submitting the </B><B>Form 6-K</B><B> in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;</B><B>101(b)(7)</B><B>: </B><FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country
exchange on which the registrant&#146;s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant&#146;s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-</B><B>2(b)</B><B> under the
Securities Exchange Act of 1934.</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Yes <FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No <FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-</B><B>2(b)</B><B>: 82 -</B>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Oncolytics Biotech Inc.</B><BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: March 6, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Doug Ball
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Doug Ball&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o35129o3512900.gif" alt="(ONCOLYTICS LOGO)"></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">210,1167 Kensington Cr. N.W.<BR>
Calgary, Alberta <BR>
Canada T2N 1X7</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<HR noshade size="2" width="100%" align="center">



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Issuance of 19th U.S. Patent</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB &#151; March&nbsp;6, 2007 </B>&#150; Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
(&#147;Oncolytics&#148;) has been granted U.S. Patent 7,186,542 entitled &#147;Method of Extracting Virus from
Cell Culture.&#148; The claims describe a method of producing infectious reovirus that allows for the
removal of cell debris by filtration and concentration of the filtrate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This patent expands on similar manufacturing patents secured by the Company,&#148; said Dr.&nbsp;Matt
Coffey, Chief Scientific Officer of Oncolytics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase
I and Phase II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation and chemotherapy. For further information about
Oncolytics, please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This news release contains forward-looking statements, within the meaning of Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others,
the Company&#146;s belief as to the importance of the issuance of this patent, the safety and efficacy
of the reovirus, the Company&#146;s expectations as to the potential applications of the patented
technology and other statements relating to anticipated developments in the Company&#146;s business and
technologies, involve known and unknown risks and uncertainties that could cause the Company&#146;s
actual results to differ materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the efficacy of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment,
the success and timely completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals and uncertainties related to the regulatory process.
Investors should consult the Company&#146;s quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these forward-looking
statements.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cathy Ward
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Erika Moran</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">210, 1167 Kensington Cr NW
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">600, 205 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11 Stone St, 3rd Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Alberta T2N 1X7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Calgary, Alberta T2P 2V7
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10004</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 403.670.7377
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 403.538.4845
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 403.283.0858
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 403.266.2453
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->


</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o35129o3512900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o35129o3512900.gif
M1TE&.#EAY@`[`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)R<G*6EI:VMK;6UM;V]O<[.SM[>WN?G
MY^_O[_?W]___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````Y@`[```(_@`Y"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ERTQP)Q)LZ;-
MFSASZMS)LZ?/GT"#@M1@04$"!@F,+H!PX8+0IU`I8J"@H``"`@<06"5``,$`
M`P8:2-`0M:Q9@P^X)OW*54!;K6`3('A@X:S=IQ@>('`KX("""60-2H![E4`#
MIW<3[ZQ`P,"!!0XJ!%XXP4%6!4L5:ZZIX8$"`P@62"2*`('<!IM3NU1`0"Z%
M#!0[$UA0@('JVRC3)C`@TZ(&#`,8+%"`N[A(#*$9],:8H8%PV\:C;\1@%`%B
MC1>Z-D`MO;M%TPB6_F^D<-0`;._H(5H0P,`!2`:AN:>?OU"!A`23.VK8;4`"
M_?\'76!``A"(=`$"#!`'X(("8::`>!\M8(`"UZ&D084,KJ0!`@?X-]*&V[&4
M7X8J53"@AR.5!AV)Z24W(DB>+8`ABST1]>)##(18$F.M':1!!!&,99`%#3B`
M(D(7%+E=>Q?\YB,'/Q;)@'`/0%B0@`E,L)!G1]VH`6;6";2?40I\=E0!8#E&
M`(82</6`0AL.P)6<1DI@)0822""G6P<D0$$$%#Q400'VG61``>X9A$$`"!@0
M04$:2""``04BU!D`[,D5&J9'#E04II@=U0!K!TAV$'(%U`5G:0<T\.(#_F!5
MZ)QS4\[F0`0+/!"!`Q!*`-J;!UG`P`%@/0#!`Q(XP)Y@!$P*I+`1%.!6IPH=
M>("6)EDE'T$7##`J`=0B!:Q!V1$0`8886`EE`H:I.A`&$'"E'+D&+%!!0ZP5
M$,%Y4%I00`$S$H1<APL-EL"X!%F@UHV""=``PA5=4!NU(=6[HL`%'!!!59TV
MD$"B`Y&E`;$0KTK`O`?!ZNB0"#3@[D*C(N"A!A2T%K#`"C!`,4$2*&"L011P
MR`##0SK0,M&"RH5M2:!M^RZQ&9C6'T$/+/"H00@NH"Y"_C)0<LA&E1RU`4LS
M9+1P&3R`9ME(%K#`S@/==Y1![<W]$*Y6.?!`_@469(`TUQS"[5&](`N<E$RD
M1A#8L(4+9$%8#=SK$)A;<X#<<.BV_#)#@QV`E,P-(9>`X!P,ID#C'!SJP,W5
M[F4``,TF8$'EP2)(^D8:3/@U!NSVML!P'F[G-`<6F';UY&[#G3L#`VR.JN0/
MZ39U0X^#6W!\!K7&P.8.:7`A!L,&H$!H#Q7UMJ$)#,_!!0N$-]"9CWI<L@;P
M%4![01C4^[5`$L]%K@(NB\B7%A`HA^3O?)8J'8)*UH!&[2\B$F-``6XGD`P<
M130EP4!M$G"J`@Q@.18L#04@X`#U24@!!9R<7+96O>%=8'S<6\B&&'`\AF"@
M*Z3KF=X,,D`#L.XA_AEH'P)2R)"Y7$PD>E+`C<!'`/'D+RD?4]^&^C0_",ED
M0P5PE:(:I;['-8!M`J$=`B*@/B0)`($)D<"4RL@:`J7KC1:00`VAI)R^>2]=
M&G"``@(PQX4L8#=@C)!>;B0@WESICUHY(D$FD(``9(P_AP+`T`R2`0@,@%$&
MF%,!&-5'_H&%*P4`P"4#$(!*G:HKBDP(!@XP@$[R#)4)25(`+CD``#"*0_SB
M0`2RTJP!;+*6]0JD0HK7`"(.!7NGFD`#K$04"53`F)#"TP0H,$(*R*1RD6K*
MN3!@@1@F;';@!.</+=>4AQ!E=C+$P`6821`GP0E*!*&`-PW8,M1YY`'L_AHG
MC7!'DP8F0)^^$0X']YD>^@U').29R]\(FAH&S`9Z'CD`!%+)4..L\F,+E4A>
M.`1-;C7E?NMCR`70J9!I/G,"\]1`!28@QW%6(`(/R"6DL)4!.UDDC@IY`+8N
M8$^!18"&'Z$*?#+ZD+P,:Y((P8``8.HUHE%EF`GRU8,2TDV'6:"C`O%5-W\X
M@;"4DZKR`0`%$R+!A.1N`;:!E5E_YTJ-/*"$"LI(I#A$`!D*P%BM4@@950F`
MXT6@K@HAP`,]"9D'7B``(%W?;-(G`*PZ!"F!_1'9"J!*`4`4)"44#E'A!$4$
M_$T#`DB7!"2I*('\5*\4XB90%6*`P1*/0MW,U*FC(N78"YA2`&-%R+`BN[ZK
MF%5^\FSK3Q/KH^=@L")G;>`\WT6`\3W@AQ>@Z$!@VMJV3M>424U*@FAG@0B,
M<9X8X`YU+O)<A<C'`JY-E]=85Z7-\A`I$@0H#R_PL:/(]R5$=6_W](L2XDXD
M`A^3J#`/4E.YR,4!_.6)3"LJ$95Q29YF#9*W<C1&!C-X,(0*3:[RE*<)_#0K
M0CN8A4><.V(AP`%HQ0R*ER277-UWQ`OJV6Z2<B@TF08"_H7Q/C'P&[(T2<=`
1#K*0ATSD(AOYR$CF0$```#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
